News
Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...
With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback